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assess model improvement over baseline.  Results: We re-
cruited 125 patients. The lacunar group (n = 65) had lower 
tissue plasminogen activator (t-PA) levels in unadjusted 
(7.39 vs. 8.59 ng/ml, p = 0.029) and adjusted (p = 0.035) anal-
yses compared with the cortical group (n = 60). There were 
no significant differences in the other plasma biomarkers. 
The results for t-PA were consistent with an updated meta-
analysis, although the effect remains non-significant (stan-
dardized mean difference –0.08 (95% CI –0.25 to 0.09)). The 
baseline regression model explained 29% of the variance in 
quantitative WMH (R 2 0.289). Inflammatory biomarkers 
showed minor improvement over baseline (R 2 0.291), but 
the other plasma biomarkers did not improve the baseline 
model.  Conclusion: Plasma t-PA levels appear to differ be-
tween lacunar and cortical stroke subtypes, late after stroke, 
independent of age, sex and vascular risk factors and may 
reflect endothelial dysfunction. Except for a minor addition-
al predictive effect of inflammatory markers, plasma bio-
markers do not relate to WMH severity in this small stroke 
population.  © 2015 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Background: The cause of lacunar ischemic stroke, a clinical 
feature of cerebral small vessel disease (SVD), is largely un-
known. Inflammation and endothelial dysfunction have 
been implicated. Plasma biomarkers could provide mecha-
nistic insights but current data are conflicting. White matter 
hyperintensities (WMHs) are an important imaging biomark-
er of SVD. It is unknown if plasma biomarkers add predictive 
capacity beyond age and vascular risk factors in explaining 
WMH.  Methods: We prospectively recruited patients pre-
senting with non-disabling ischemic stroke, classifying them 
clinically and with the help of MRI as lacunar or cortical. We 
measured biomarkers of inflammation, endothelial dysfunc-
tion and hemostasis for >1 month after stroke and compared 
biomarker levels between stroke subtypes. We quantitative-
ly calculated WMH. We used multiple linear regression anal-
ysis to model WMH as a function of age, sex, hypertension 
and smoking (the baseline model). We fitted exploratory 
models using plasma biomarkers as predictor variables to 
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 Introduction 
 The cause of lacunar ischemic stroke, a clinical feature 
of cerebral small vessel disease (SVD), is largely unknown 
although systemic inflammation, endothelial dysfunc-
tion, failure of the blood–brain barrier or occlusive mi-
crothrombus have been implicated  [1–5] .
 Plasma biomarkers of inflammation, endothelial dys-
function and hemostasis may provide mechanistic in-
sights, although if measured too soon after stroke they 
might simply reflect the acute effects of stroke rather than 
background pathway activity.
 The MRI features of SVD include white matter hyper-
intensities (WMHs) and are associated with ischemic 
and hemorrhagic stroke and dementia  [6] . WMH predict 
an increased risk of stroke  [6] and are associated with 
poor functional outcomes following stroke  [7] . Plasma 
biomarkers may predict outcome after stroke  [8] and 
could have a role in the management of stroke patients 
 [9] .
 The relationship between plasma biomarkers and im-
aging biomarkers of SVD is not fully understood. System-
atic reviews  [2, 10, 11] are impeded by between-study het-
erogeneity and they differ in their conclusions. Generally, 
plasma biomarkers are raised in lacunar stroke compared 
with non-stroke healthy controls (used in most studies) 
but differences here are unsurprising, especially in the 
acute phase of stroke. The situation is less clear when la-
cunar stroke is compared to other ischemic stroke sub-
types. In a systematic review and meta-analysis  [10] , we 
found differences in levels of fibrinogen, D-dimer, von 
Willebrand factor (vWF) and interleukin-6 (IL-6) be-
tween lacunar and non-lacunar stroke, and no difference 
or conflicting evidence for other biomarkers.
 In 2 large population studies of subjects without stroke, 
higher inflammatory biomarkers were independently as-
sociated with higher WMH volumes  [1, 12] but not in 
3 other studies  [13–15] . Biomarkers of endothelial activa-
tion were associated with WMH in a cross-sectional anal-
ysis  [16] and with WMH progression  [4] . Flow-mediated 
dilatation studies have shown the presence of endothelial 
dysfunction in lacunar stroke patients compared with 
non-stroke controls  [17] .
 Prior stroke studies often take the plasma samples too 
early making it difficult to isolate underlying trends inde-
pendent from an acute phase response. Few studies as-
sessed a range of biomarkers simultaneously in one pop-
ulation.
 The purpose of this study was (1) to determine if there 
were differences in levels of plasma biomarkers of (a) in-
flammation, (b) endothelial dysfunction or (c) hemosta-
sis between lacunar and cortical stroke subtypes, well af-
ter the acute event, as representative of 3 potential SVD 
mechanisms, adjusted for age and major vascular risk fac-
tors; (2) to update our meta-analysis and place current 
findings into context and (3) to assess the association be-
tween the 3 plasma biomarker groups and WMH, irre-
spective of stroke subtype.
 Methods 
 Our definition of SVD is in accordance with the STRIVE neu-
roimaging reporting guidelines  [18] .
 Patients 
 We prospectively recruited patients, as consecutively as pos-
sible, who presented with ischemic stroke of lacunar or mild (i.e. 
non-disabling) cortical subtype seen at our hospital stroke ser-
vice, as detailed previously  [19] . Patients with cortical stroke act-
ed as controls because they have many similar risk factors, med-
ications and extent of damage due to the acute ischemic stroke to 
patients with lacunar stroke, thus controlling for potential con-
founders and allowing us to differentiate findings specific to 
SVD. We excluded patients with contraindications to MR, hem-
orrhagic stroke or severe stroke, that is, disabling total anterior 
circulation stroke. The study was approved by the local research 
ethics committee (2002/8/64), and all patients gave written in-
formed consent.
 Patient Investigations 
 Patients were assessed at presentation by an experienced stroke 
physician and all underwent investigations as follows: brain imag-
ing on a 1.5T research MR scanner with a standardized protocol 
(details available on request), carotid Doppler ultrasound and elec-
trocardiogram. We recorded past medical histories including hy-
pertension, diabetes, hypercholesterolemia and smoking, and 
measured the blood pressure and blood lipids as per the usual 
stroke patient assessment.
 Stroke Subtype 
 We assessed stroke severity with the National Institute for 
Health Stroke Scale (NIHSS)  [20] (but did not use NIHSS as selec-
tion criteria) and classified the stroke clinical syndrome (lacunar 
or cortical) according to the Oxfordshire Community Stroke Proj-
ect  [21] . We defined ‘lacunar stroke’ as per the classical clinical 
lacunar syndromes (pure motor weakness or sensory loss or both 
in face and arm, arm and leg or all three, ataxic hemiparesis or 
clumsy hand dysarthria syndrome). We defined ‘mild cortical 
stroke’ as a maximum clinical deficit of either one of the following: 
weakness or sensory loss in the face, arm or leg, or loss of higher 
cerebral function (dysphasia or neglect), or weakness in more than 
one limb in the presence of loss of higher cerebral function (all in 
keeping with a partial anterior circulation stroke) or a homony-
mous hemianopia suggestive of occipital cortical infarct (in keep-
ing with a cortical posterior circulation stroke).
 We then assessed whether a recent infarct on MR was firstly 
present and secondly whether it was cortical or lacunar. We based 
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the final stroke subtype classification on both the clinical and ra-
diological classification. Where the clinical classification differed 
from the radiological classification, the radiological classification 
was used – using clinical criteria alone can result in misclassifica-
tion of infarcts in up to 20% of cases  [22] . Where an infarct on 
imaging was absent, an expert panel with all available information 
assigned the final stroke subtype.
 Plasma Biomarkers 
 All patients had their blood sampled after a minimum of 1 and 
maximum of 3 months following the stroke to avoid the acute 
phase. Samples were spun and frozen for batch analysis, blind to 
clinical data. We measured markers of inflammation (C-reactive 
protein (CRP) tumor necrosis factor-alpha (TNF) and IL-6), en-
dothelial activation (vWF and intracellular adhesion molecule-1 
(ICAM)) and thrombotic/fibrinolytic activity (fibrinogen, tissue 
plasminogen activator (t-PA) antigen and D-dimer). Intra- and 
inter-assay variation on biomarker testing was between 3.3 and 
12.5% (online suppl. table 1; for all online suppl. material, see www.
karger.com/doi/10.1159/000438494).
 Image Analysis 
 All scans were reviewed by a neuroradiologist for the index 
 infarct and rated for SVD features using standardized scales  [23–
25] including the Fazekas scale for WMH. A quantitative, volu-
metric measure of WMH (in mm 3 ) was also calculated, as de-
scribed previously  [26] . We corrected for head size by dividing the 
quantitative WMH load by the intracranial volume. We verified 
the correlation between the visual WMH rating and the quantita-
tive value.
 Statistical Analysis 
 We assessed differences in patient demographics and plasma 
biomarkers between stroke subtypes using Student’s t test, the 
Mann–Whitney U test and the chi-square test, as appropriate. 
Quantitative WMH and some plasma biomarkers (CRP, TNF, IL-6 
and D-dimer) were not normally distributed; so we log trans-
formed these data.
 We explored the association between stroke subtypes and plas-
ma biomarkers with multiple linear regression analysis which al-
lowed us to control for age, sex and vascular risk factors.
 We used multiple linear regression to assess the contribution 
of plasma biomarkers in explaining variance in quantitative WMH 
volume (n = 98, 27 scans were unavailable for WMH quantifica-
tion), irrespective of stroke subtype. We repeated the modeling 
with visually rated WMH, for which the full data set was available 
(n = 125).
 We used standardized units (mean = 0, SD = 1) for all plasma 
biomarkers in the regression models. The standardized data have 
no units and are on the same scale, so different biomarkers can 
be added together into summed variables which reduces the 
number of predictor variables to help avoid model over-fitting. 
We verified the correlation between the components of the 
summed variables. The summed variables were the following: in-
flammation (INF) (CRP + TNF + IL-6), endothelial dysfunction 
(END) (vWF + ICAM) and thrombosis (THR) (t-PA + D-di-
mer + fibrinogen).
 We fitted a baseline model with quantitative WMH volume as 
the outcome measure and age, sex, hypertension and smoking sta-
tus as the predictor variables. Patients with a past history of to-
bacco use were classified as non-smokers, if they were non-smok-
ers at the time of stroke. Two patients (1 lacunar stroke and 1 cor-
tical stroke) had missing data for smoking status. We fitted 4 
further models: Model 1 (baseline + inflammation (INF)), Model 
2 (baseline + endothelial dysfunction (END)), Model 3 (baseline + 
thrombosis/fibrinolysis (THR)) and Model 4 (baseline + INF + 
END + THR).
 We compared each model for improvement over baseline. 
Model improvement was defined as a reduction in residual stan-
dard error (RSE) and increase in adjusted r-square (R 2 ).
 We checked for multicollinearity between predictor variables 
using variance inflation factor. We checked model assumptions as 
follows: independence, linearity, constancy of variance and nor-
mality in the residuals. Alpha level for significance was p < 0.05. 
All analyses were performed with the statistical programming 
 language R version 3.0.1 (http://www.r-project.org/)  [27] .
 Meta-Analysis 
 We used the Review Manager 5 software (The Cochrane Col-
laboration) to update our prior meta-analysis  [10] , calculating the 
standardized mean difference (SMD) using the inverse variance 
method and a fixed effects model with 95% CIs.
 Results 
 We recruited 125 patients: 65 with lacunar stroke and 
60 with cortical stroke. The mean age of the total cohort 
was 66.4 ± 11.4 years and the median NIHSS score was 
1 (Q1–Q3 1–2). The median time from stroke onset to 
blood sampling was 54.4 (Q1–Q3 36–74) days. Patient 
characteristics and plasma biomarkers by stroke subtype 
are listed in  table 1 .
 Differences between Stroke Groups 
 The lacunar group had fewer men (39 vs. 51, p = 0.004), 
were younger (64 vs. 69 years, p = 0.015) and suffered less 
atrial fibrillation (2 vs. 9, p = 0.042) compared with the 
cortical group ( table 1 ).
 Plasma Biomarker Association with Lacunar Stroke 
 The lacunar group had lower t-PA levels compared 
with the cortical group (7.39 vs. 8.59 ng/ml, p = 0.029) in 
unadjusted analyses ( table  1 ) and after adjustment for 
age, sex, hypertension, smoking, diabetes and atrial fibril-
lation (p = 0.035;  table 2 ). There were no differences in 
the other plasma biomarkers between lacunar stroke and 
cortical stroke whether adjusted or not (online suppl. ta-
bles 2–4).
 To determine if the reduced t-PA was related to smok-
ing, we repeated the analysis in non-smokers only (lacu-
nar stroke, n = 40 vs. cortical stroke, n = 46). t-PA levels 
remained lower in lacunar stroke (online suppl. table 5). 
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Although the difference became non-significant when 
adjusted for age, sex, hypertension and diabetes, the 
change was slight, the regression coefficients and 95% 
CIs were similar  [28] being –1.33 (95% CI –2.53 to –0.13) 
vs. –1.37 (95% CI –2.84 to 0.09) ( table 2 and online sup-
pl. table  6, respectively) and may reflect the reduced 
sample.
 Meta-Analysis 
 On addition of our study to the 4 prior studies (new total 
300 lacunar strokes), we show lower t-PA in lacunar versus 
non-lacunar stroke although the difference was not signif-
icant ( fig. 1 ). Addition of our data moves the SMD from 
0.02 (95% CI –0.18 to 0.21) to –0.08 (95% CI –0.25 to 0.09).
 Biomarkers and WMH (All Patients: Lacunar and 
Cortical) 
 Quantitative WMH and plasma biomarkers were 
available for 98 patients. The baseline model (age, sex, 
hypertension and smoking status) explained 29% of the 
variance in quantitative WMH (RSE 1.081, R 2 0.289) with 
age, hypertension and smoking as significant predictors 
( table  3 ). Model 1 (baseline + INF) showed minor im-
provement over baseline (RSE 1.066, R 2 0.291). Models 
2 (END), 3 (THR) and 4 (INF + END + THR) did not 
improve the baseline model. All models met model as-
sumptions. There were no negative correlations between 
the components of the summed variables meaning a rise 
in one plasma marker was not offset by a fall in another 
(online suppl. table 7).
Table 2.  Association of t-PA with lacunar stroke subtype (n = 125)
Regression coefficient 
(95% CI)
p value
Lacunar stroke subtype –1.312 (–2.531 to –0.093) 0.035*
Age –0.017 (–0.073 to 0.038) 0.530
Male sex 0.542 (–0.740 to 1.824) 0.404
Hypertension 0.393 (–0.806 to 1.593) 0.517
Smoking 1.027 (–0.277 to 2.333) 0.121
Diabetes 0.266 (–1.324 to 1.855) 0.741
Atrial fibrillation 0.240 (–1.854 to 2.334) 0.820
 * p < 0.05.
Table 1.  Comparing patient characteristics and plasma biomarkers between lacunar and cortical stroke
Lacunar stroke (n = 65) Cortical stroke (n = 60) p value
Male, n (%) 39 (60) 51 (85) 0.004*
Age, years, mean (SD) 64.1 (11.4) 69.0 (10.9) 0.015*
Hypertension, n (%) 37 (57) 39 (65) 0.458
Diabetes, n (%) 14 (21.5) 5 (8.3) 0.071
Current smoker, n (%) 24/64 (37.5) 13/59 (22.0) 0.095
NIHSS, median (Q1–Q3) 2 (1–3) 1 (0.75–2) 0.404
Time to sample, days, median (Q1–Q3) 56 (38–74) 52 (36–77) 0.894
Ischemic heart disease, n (%) 8 (12.3) 16 (26.6) 0.070
Atrial fibrillation, n (%) 2 (3.1) 9 (15) 0.042*
Hyperlipidemia, n (%) 26/64 (40.6) 23 (38.3) 0.939
Total cholesterol, mmol/l, mean (SD) 5.07 (1.10) (n = 57) 5.06 (1.13) (n = 53) 0.949
Positive family history of stroke, n (%) 10/64 (15.6) 4/58 (6.9) 0.220
Inflammation, median (Q1–Q3)
CRP, mg/l 1.37 (0.84–3.44) 1.73 (0.97–3.54) 0.748
TNF, pg/ml 0.92 (0.72–1.33) 0.88 (0.76–1.23) 0.972
IL-6, pg/ml 2.57 (1.91–4.12) (n = 64) 2.58 (1.90–3.77) 0.994
Endothelial dysfunction, mean (SD)
ICAM, ng/ml 162.78 (57.97) 159.27 (46.1) (n = 56) 0.711
vWF, IU/dl 129.31 (41.49) 131.7 (39.2) 0.741
Thrombosis/fibrinolysis
Fibrinogen, g/l, mean (SD) 3.84 (0.61) (n = 64) 3.93 (0.67) (n = 59) 0.452
t-PA, ng/ml, mean (SD) 7.39 (3.13) 8.59 (2.92) 0.029*
D-dimer, ng/ml, median (Q1–Q3) 100 (73–157) 128.5 (73.25–182.5) 0.498
 * p < 0.05.
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 Visually rated WMH correlated strongly with quanti-
tative WMH (r = 0.84, 95% CI 0.77 to 0.89). Models for 
visually rated WMH show similar results to quantitative 
WMH (online suppl. table 8).
 Discussion 
 We show a difference in t-PA levels between lacunar 
stroke and mild cortical stroke from plasma sampled well 
after the acute phase, independent of age, sex and risk 
factors. We did not find differences between stroke sub-
types for biomarkers of inflammation (CRP, TNF and 
IL-6), endothelial dysfunction (vWF and ICAM) or oth-
er markers of hemostasis (fibrinogen and D-dimer). Ex-
cept for a minor additional predictive effect of summed 
inflammatory markers, plasma biomarkers did not con-
siderably improve the baseline model in explaining 
WMH.
 t-PA 
 t-PA is a glycoprotein released mainly by endothelial 
cells  [29, 30] to mediate the breakdown of thrombus. Its 
use as a thrombolytic agent might lead to the assumption 
that endogenous t-PA is protective against thrombosis 
 [30] . However, higher t-PA antigen levels are associated 
Table 3.  Explaining variance in quantitative WMH with different predictor variables (n = 98)
Predictor variables RSE R2
Baseline model
Age‡, male sex, hypertension*, smoking† 1.081 0.289
Model 1
Age‡, male sex, hypertension*, smoking† + inflammation 1.066 0.291
Model 2
Age‡, male sex, hypertension*, smoking† + endothelial activation 1.098 0.285
Model 3
Age‡, male sex, hypertension*, smoking† + thrombosis 1.098 0.278
Model 4
Age‡, male sex, hypertension*, smoking† + inflammation + endothelial activation + thrombosis 1.094 0.285
 Inflammation = log CRP, log TNF, log IL-6. Endothelial activation = vWF, ICAM. Thrombosis = t-PA, log D-dimer, fibrinogen. 
For RSE, bold indicates improvement over baseline, i.e. reduction in RSE. For R2, bold indicates improvement over baseline, i.e. in-
crease in R2..
* p < 0.05, † p < 0.01, ‡ p < 0.001.
Lindgren 1996 (2 days)
Jood 2005 (10 days)
Tuttolomondo 2009a (12 h)
Tuttolomondo 2009b (12 h)
Wiseman (2 months)
Study or subgroup
Total (95% Cl)
Heterogeneity: Chi2 = 14.68, df = 4 (p = 0.005); p2 = 73%
Test for overall effect: Z = 0.88 (p = 0.38)
Lacunar Non-lacunar SMD SMD
IV, Fixed, 95% ClSD
3
4.6
14
13.3
3.13
Total
33
124
32
46
65
300
Mean
11
11.8
27
28
7.39
SD
2
5.7
21.48
16.29
2.92
Total
34
73
41
50
60
258
IV, Fixed, 95% Cl Year
0.58 [0.09, 1.07] 1996
–0.16 [–0.45, 0.13] 2005
–0.37 [–0.84, 0.09] 2009
0.27 [–0.14, 0.67] 2009
–0.39 [–0.75, –0.04] 2015
–0.08 [–0.25, 0.09]
Mean
9.5
12.6
34
24
8.59
–2 –1 0 1 2
Lower in lacunar Higher in lacunar
 Fig. 1. Forest plot comparing t-PA levels between lacunar stroke and non-lacunar stroke. Values in bracket after 
study refers to time to blood draw. 
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with the risk of coronary heart disease in generally healthy 
populations  [29] . This may reflect increased endothelial 
disturbance resulting in increased t-PA secretion or else 
increased levels of its inhibitor, t-PA inhibitor (PAI-1), 
resulting in increased levels of circulating complexes 
with t-PA  [29–31] . Although smoking did not influence 
outcome after recombinant t-PA in IST-3  [32] some  [33, 
34] , but not all  [35] , observational studies suggest that 
smokers respond better to recombinant t-PA than non-
smokers.
 We found lower t-PA in those with lacunar as com-
pared to those with cortical stroke. Reduced t-PA could 
mean lacunar stroke patients have reduced vascular dam-
age – vWF levels were also lower in lacunar stroke but 
ICAM levels were higher (neither statistically signifi-
cant). Alternatively, lacunar stroke patients might have 
increased endogenous fibrinolytic activity, if lower t-PA 
levels reflect lower levels of its inhibitor, PAI-1.
 Knottnerus et al.  [36] found significantly lower t-PA 
levels (and significantly higher PAI-1 levels) in 43 lacunar 
stroke patients with an isolated infarct versus 53 lacunar 
stroke patients with concurrent extensive WMH, hypoth-
esizing that patients with extensive WMH lack the pro-
tective effect of PAI-1 in t-PA–induced tissue damage.
 In our recent meta-analysis  [10] , t-PA was significant-
ly higher in lacunar stroke patients than in non-stroke 
controls but did not differ significantly between patients 
of lacunar stroke and other stroke subtypes, although 
data are limited and the timing of sample collection could 
be confounding. Our samples were collected well after the 
acute phase and are more likely to reflect underlying 
pathway activity. The updated meta-analysis, including 
the current data, moves the evidence in favor of lower 
t-PA in lacunar stroke rather than non-lacunar stroke 
( fig. 1 ). The largest study to date to find lower levels of 
t-PA in small vessel stroke is the Sahlgrenska cohort, 
 Sweden  [37] : among 600 patients with ischemic stroke, 
including 124 with small vessel stroke, small vessel stroke 
patients had higher t-PA levels compared to non-stroke 
controls in the acute phase and at 3 months, but lower 
t-PA levels compared to patients with other stroke sub-
types. The reduced t-PA is consistent with the impaired 
blood–brain barrier function found in the same cohort 
previously  [38] .
 The lacunar group were significantly younger with 
fewer cases of atrial fibrillation and more smokers (non-
significant) than the cortical group, although the associa-
tion of lacunar stroke with lower t-PA was independent 
of these, and the pattern persisted in analysis restricted to 
non-smokers.
 WMH and Biomarkers 
 Age, hypertension and smoking were significant pre-
dictors of WMH. The inflammatory biomarker summed 
variable appeared to improve the model (slight reduction 
in the RSE) but the additional explanatory power was 
small and could be interpreted as no model improve-
ment. On the other hand, a similar effect size confirmed 
in a larger study would indicate a modest but important 
effect of plasma markers of inflammation on WMH pre-
diction. The other plasma markers did not have any ad-
ditional explanatory power. Studies that have measured 
WMH in non-stroke populations typically involve older 
people. We have clearly shown age to be the most impor-
tant predictor variable in the assessment of WMH and 
thus correcting for age is crucial.
 Two large studies  [1, 12] showed independent associa-
tions between higher plasma inflammatory biomarkers 
and more WMH but had wide age ranges. However, Rouhl 
et al.  [39] found no difference in CRP levels between 81 
patients with and 265 patients without extensive WMH, 
Wersching et al.  [13] found no association between CRP 
and WMH among 321 older stroke-free participants, 
Baune et al.  [40] found no association between TNF and 
WMH among 268 community-dwelling participants and 
Aribisala et al.  [41] found no association between inflam-
mation (a latent factor comprising CRP, fibrinogen and 
IL-6) and WMH among 634 community-dwelling older 
people of near-identical age. Thus, it is possible that wide 
age ranges in some studies inflated associations between 
inflammatory markers and WMH. Shoamanesh et al.  [15] 
found no association between some inflammatory bio-
markers (including CRP, IL-6 and TNF) and SVD (de-
fined as presence of silent infarcts and/or extensive WMH) 
in a large cohort of younger stroke-free Framingham par-
ticipants (n = 522; mean age 60 years) but did associate 
ICAM with SVD. We found no association between ICAM 
and WMH in the present study but have much less power 
than the Framingham study. Our systematic review and 
meta-analysis  [10] found no difference in ICAM levels be-
tween lacunar stroke and other stroke subtypes although 
only a few studies contributed data. ICAM was non-sig-
nificantly higher in lacunar stroke patients than cortical 
stroke patients in the present study.
 Conclusion 
 Despite being small (n = 125) and cross-sectional, our 
study uses thorough methods and adds new information. 
Our findings show a difference in t-PA levels between 
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 lacunar and cortical stroke which should be verified in 
other data sets. Future studies should obtain plasma sam-
ples in the chronic phase after stroke and concentrate on 
longitudinal associations, especially the role of t-PA in 
stroke subtypes as it could help explain mechanisms. A 
large prospective study of accurately phenotyped stroke 
patients would be helpful. It is important to not only con-
trol for age specifically, but also hypertension and smok-
ing when modeling features of SVD such as WMH and 
biomarkers.
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